P437
|
Mapping the treatment pathway for metastatic uveal melanoma (mUM) patients in England: A qualitative pilot study
|
Elisabeth Adams1, Chih-Yuan Cheng1, Joseph Sacco2, Sarah Danson3, Pippa Corrie4, Paul Nathan5, Peter Szlosarek6, Joanne Upton2, Abolore Amuludun6, Toby Toward7
|
1Aquarius Population Health Limited, London, United Kingdom 2The Clatterbridge Cancer Centre, Wirral, United Kingdom 3Weston Park Hospital, Sheffield, United Kingdom 4Addenbrooke's Hospital, Cambridge, United Kingdom 5Mount Vernon Cancer Centre, London, United Kingdom 6Barts Cancer Institute, London, United Kingdom 7Immunocore Limited, Abingdon, United Kingdom
|
Chemotherapy | Checkpoint blockade | Clinical trial | Epidemiology | Immune monitoring | Immune toxicity | Surgery | Solid tumors | Targeted therapy
|
P438
|
Continued Challenges and Opportunities in Oncologists’ COMPREHension of Clinical Immunology and its relationship with cancer immunotherapy
|
Tara Herrmann1, Charlotte Warren1, Haleh Kadkhoda2, Lianne Wiggins3
|
1Medscape Education Oncology, New York, NY, USA 2Medscape Education, New York, NY, USA 3SITC, Milwaukee, WI, USA
|
Checkpoint blockade | Solid tumors
|
P439
|
PDL-1 status and value for Extrapulmonary small cell carcinomas
|
Mohammed Salhab1, Yiqin Xiong1, Karen Dresser1, Benjamin Chen1, James Liebmann1
|
1University of Massachusetts, worcester, MA, USA
|
Checkpoint blockade | Tumor stroma | Tumor infiltrating lymphocytes (TILs) | Tumor microenvironment
|